The Form 4 filing, an SEC report of insider stock activity, was filed on November 19, 2026. It covers sales from November 17 through November 18, 2026, by Lyn Baranowski, Avalyn Pharma's chief executive officer.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-17 |
| Date of Latest Transaction | 2026-11-18 |
| Buy/Sell | sell |
| Transaction Count | 5 |
| Shares Transacted | 52,500 |
| Price | $27.84 |
| Total Transaction Value | $1,461,457.16 |
| Insider | |
| Ticker Symbol | AVLN |
| Company | Avalyn Pharma Inc. |
| Insider Name | Baranowski Lyn |
| Insider Title | Chief Executive Officer |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 0 |
| Position Size Change | 100.00% |
| Filing | |
| Filing Date | 2026-11-19 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of AVLN shares, reported under transaction code S. The five reported transactions appear in a single filing.
What was the average price of the transaction?
The average sale price was $27.84 per share, rounded to cents. Prices for each of the five separate sales were not included in the available details.
How did this transaction affect the insider's holdings?
Lyn Baranowski sold 52,500 shares, equal to 100.00% of the reported share balance before the sales. Zero shares were listed afterward. The available details do not establish holdings in other accounts or types of securities.
What's the total transaction value?
The five sales had a total value of $1,461,457.159. Rounded to cents, that is $1,461,457.16, as shown above.
Are there any special circumstances around this transaction?
The filing information includes a Rule 10b5-1 reference or checkbox. These trading plans set instructions in advance. The available details do not show which of the five sales that reference covers. Footnote text and plan terms were not provided. The plan's start date and trading schedule remain unknown.
For research purposes only; not investment advice.